TW202300171A - Mazdutide的應用 - Google Patents

Mazdutide的應用 Download PDF

Info

Publication number
TW202300171A
TW202300171A TW111123396A TW111123396A TW202300171A TW 202300171 A TW202300171 A TW 202300171A TW 111123396 A TW111123396 A TW 111123396A TW 111123396 A TW111123396 A TW 111123396A TW 202300171 A TW202300171 A TW 202300171A
Authority
TW
Taiwan
Prior art keywords
dose
week
drug
uric acid
administered
Prior art date
Application number
TW111123396A
Other languages
English (en)
Chinese (zh)
Inventor
安培
鄧煥
Original Assignee
大陸商信達生物製藥（蘇州）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商信達生物製藥（蘇州）有限公司 filed Critical 大陸商信達生物製藥（蘇州）有限公司
Publication of TW202300171A publication Critical patent/TW202300171A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
TW111123396A 2021-06-25 2022-06-23 Mazdutide的應用 TW202300171A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110711050.0 2021-06-25
CN202110711050 2021-06-25

Publications (1)

Publication Number Publication Date
TW202300171A true TW202300171A (zh) 2023-01-01

Family

ID=84544128

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111123396A TW202300171A (zh) 2021-06-25 2022-06-23 Mazdutide的應用

Country Status (9)

Country Link
US (1) US20240293513A1 (https=)
EP (1) EP4360641A4 (https=)
JP (1) JP2024524273A (https=)
KR (1) KR20240027053A (https=)
CN (1) CN117597135A (https=)
AU (1) AU2022298841A1 (https=)
CA (1) CA3224043A1 (https=)
TW (1) TW202300171A (https=)
WO (1) WO2022268174A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250021331A (ko) * 2022-06-01 2025-02-12 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 mazdutide를 사용하는 치료 방법
WO2025073289A1 (en) * 2023-10-03 2025-04-10 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating diabetes and obesity
WO2025073288A1 (en) * 2023-10-03 2025-04-10 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating adolescent obesity
CN120676965A (zh) * 2023-11-07 2025-09-19 深圳信立泰药业股份有限公司 多重受体共激动剂化合物及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI700291B (zh) * 2015-06-22 2020-08-01 美國禮來大藥廠 升糖素及glp-1共激動劑化合物
WO2019171352A2 (en) * 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity
KR20250021331A (ko) * 2022-06-01 2025-02-12 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 mazdutide를 사용하는 치료 방법

Also Published As

Publication number Publication date
CN117597135A (zh) 2024-02-23
JP2024524273A (ja) 2024-07-05
US20240293513A1 (en) 2024-09-05
CA3224043A1 (en) 2022-12-29
EP4360641A4 (en) 2025-10-22
KR20240027053A (ko) 2024-02-29
EP4360641A1 (en) 2024-05-01
WO2022268174A1 (zh) 2022-12-29
AU2022298841A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
TW202300171A (zh) Mazdutide的應用
RU2623023C2 (ru) Ликсисенатид и метформин для лечения диабета типа 2
US20180133290A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
EP2324853A1 (en) Lixisenatide as add-on to metformin in the treatment of diabetes type 2
US20250296973A1 (en) Treatment method using mazdutide
AU2019229469B2 (en) GLP-1 composition for treating obesity and weight management
McFarlane Antidiabetic medications and weight gain: implications for the practicing physician
JP2023510609A (ja) Ｇｌｐ－１および／またはｇｌｐ－１類似体、ならびにインスリンおよび／またはインスリン類似体を含む併用療法
EP2063909B1 (en) Formulations for therapeutic administration of thyroid stimulating hormone (TSH)
HK40110048A (en) Use of mazdutide
WO2026046202A1 (zh) Glp-1/gip肽或含有其的药物组合物的用途
HK40118093A (en) Treatment method using mazdutide
RU2834226C2 (ru) Композиция glp-1 для лечения ожирения и регулирования веса
KR20250095833A (ko) 에페글레나타이드를 유효성분으로 포함하는 약학 조성물 및 이의 투여 요법
CN108883159A (zh) 用于糖尿病性足溃疡的利拉鲁肽
WO2026037397A1 (zh) Glp-1类似物的医药用途
TW202140061A (zh) 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑
EP4531894A1 (en) Methods of using a gcg/glp1 co-agonist for therapy
WO2024243243A9 (en) Treatment of adults with overweight or obesity with or without weight-related comorbidities
HK40094446A (zh) Glp-1给药方案
HK40013213A (en) Glp-1 composition for treating obesity and weight management
HK40056898A (en) Glp-1 composition for treating obesity and weight management
JP2021528424A (ja) 対象における食後のグルコースレベルをコントロールする方法および使用